Dosage strength is associated with medication persistence with Ginkgo biloba drug products: a cohort study of ambulatory drug claims data in Germany by Sittah Czeche et al.
Czeche et al. BMC Complementary and Alternative Medicine 2013, 13:278
http://www.biomedcentral.com/1472-6882/13/278RESEARCH ARTICLE Open AccessDosage strength is associated with medication
persistence with Ginkgo biloba drug products:
a cohort study of ambulatory drug claims data
in Germany
Sittah Czeche1†, Katrin Schüssel1†, Alexandra Franzmann1, Martin Burkart2 and Martin Schulz1*Abstract
Background: Ginkgo biloba drugs (Gb) are reimbursed within the German statutory health insurance (SHI) scheme
for treatment of dementia. In 2008, a novel Gb product containing 240 mg Ginkgo extract EGb761W per tablet was
introduced aiming to facilitate medication use by incorporating the recommended daily dose in one single tablet.
The aim of this study was to evaluate the relationship between dosage strength and persistence in a representative
population of patients treated with Gb.
Methods: Retrospective cohort study in ambulatory drug claims database within the German SHI system.
Persistence was defined as continuous treatment with an allowable gap of 20% between refills. Multivariate
regression models were conducted to identify variables associated with persistence.
Results: Among 13,810 patients initiating treatment with Gb in 2008, 430 (3.1%) received a dosage strength of
240 mg, 7,070 (51.2%) a dosage strength of 120 mg and 6,310 (45.7%) dosage strengths containing less than
120 mg Gb per tablet. After 6 months, persistence was highest for patients treated with the 240 mg dosage form
(22.8% of patients), although persistence was low in general (5.7% and 0% of patients treated with 120 mg and less
than 120 mg, respectively). Risk for non-persistence was reduced in patients receiving 240 mg products compared
to 120 mg (HR = 0.63; 95%CI 0.57 – 0.70).
Conclusions: Patients initially treated with Gb 240 mg were more persistent compared to those receiving lower
dosage strengths. Nevertheless, persistence with Gb therapy is generally low and should be improved in order to
better realize therapeutic effects.
Keywords: Ginkgo biloba, Adherence, Persistence, Prescription, Drug claims database, Cohort studyBackground
Dementias are diseases of old age and will gain importance
with increasing life expectancy. Today, 1.3 million people
with dementia live in Germany with an incidence of about
200,000 per year [1]. It is assumed that dementia results in
a major burden to health care systems and society as
a whole [2]. So far, there is no cure for dementias but sev-
eral compounds have been approved for symptomatic* Correspondence: m.schulz@dapi.de
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reproduction in any medium, provided the ortreatment to improve cognitive abilities, other mental
functions, and activities of daily living: cholinesterase in-
hibitors (ChEI), the non-competitive NMDA receptor an-
tagonist memantine and standardized Ginkgo biloba dry
leaf extracts (Gb) [3].
In Germany, Gb is approved as a non-prescription
drug for the symptomatic treatment of mental losses due
to organic brain syndrome within the framework of a
general therapeutic concept in case of progressive impair-
ment or loss of mental capacities (dementia syndrome),
for vertigo, for tinnitus and for peripheral arterial occlu-
sive disease. However, only the treatment of dementia is
a reimbursable indication within the German statutoryLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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action of Gb have not been established so far, but effects
of Gb constituents on mitochondrial function are being
discussed [4,5]. From clinical trials with Gb, it has been
estimated that Gb delays progression of symptoms in
Alzheimer’s dementia by about 6–9 months [6]. In 2008,
the German Institute for Quality and Efficiency in Health
Care (IQWiG) published a favorable report on the benefit
of Gb in mild-to-moderate Alzheimer’s disease for the
therapeutic goal ‘activities of daily living’ [7]. Moreover, an
indication of a benefit of Gb regarding ‘cognitive function’,
‘general psychopathological symptoms’, and ‘quality of life
of caregivers’ was found. However, the recommendations
were restricted to a daily dose of 240 mg and to the ginkgo
biloba special extract EGb 761W. For lower daily doses,
there was no conclusive evidence of a benefit.
A recent study among primary care physicians spe-
cialized in complementary and alternative medicine
in Germany found that prescribing of Gb was strongly as-
sociated with diagnosis of Alzheimer’s disease versus other
types of dementia [8]. Moreover, in this specialized group
of physicians, Gb was the most frequent drug chosen for
treatment of dementia in more than two thirds of patients
[8]. However, prescribing rates of Gb in the general SHI
population in Germany are much lower with approxi-
mately only 14% of antidementia drug prescriptions or
5,4% of DDDs constituting Gb drugs [9,10].
It is apparent that the duration of therapy, the con-
tinuous supply of the patient with medication as well as
the appropriate taking of medication are a prerequisite
for efficacy of any drug and thus, for a successful therapy
[11]. For drugs to become effective in dementia, treat-
ment duration should be sufficiently long: the European
Medicines Agency (EMA) recommends trials of at least
24 weeks to assess a therapeutic effect in dementia for at-
tainment of drug approval [12], and the IQWiG evaluated
only trials of a duration of at least 16 weeks for assessment
of effectiveness [7]. In placebo-controlled trials with EGb
761W, therapeutic effects were more pronounced after
24 weeks than after 12 weeks of treatment [13,14].
Non-adherence is a major source of treatment failure
[15]. Non-adherence reduces the chance to experience a
treatment benefit, and non-appearance of an expected
treatment effect can result in premature discontinuation.
Reducing the complexity of medication regimens has
been found to be one of the most effective measures to
improve adherence [16,17]. This holds especially true in
patients with memory disorders [18].
In 2008, Gb products for the treatment of dementia
were available at strengths of 30, 40, 50, 60, 80, or
120 mg per tablet and as drops. To achieve the recom-
mended daily dose of 240 mg, two to eight single doses
would have been required. Therefore, a novel product
containing 240 mg EGb 761W per tablet was developedand introduced in 2008 with the aim of facilitating medi-
cation use by containing the recommended daily dose in
one single tablet.
The aim of this study was to evaluate the relation-
ship between dosage strength and treatment duration
(persistence) in a representative population of patients
treated with Gb. We hypothesized that persistence is
higher with the 240 mg dosage form.
Methods
DAPI database
The study was designed as a retrospective cohort study in
the DAPI database (www.dapi.de), which comprises claims
data of prescribed drugs dispensed by community phar-
macies in Germany at the expense of the SHI funds. For
each prescription dispensed, the collected data include a
de-identified patient code, the date of prescription, the
product identifier (PZN) and the quantity of drug product
dispensed. Via the PZN linkage to drug information sys-
tems is possible, allowing for characterization of the prod-
uct with regard to e.g. the amount and type of active
ingredient, dosage form, package size etc. Almost 90% of
the German population is covered by the SHI system [19].
The DAPI database contains a representative sample
of over 80% of the community pharmacies throughout
Germany. Information about self-medication, drugs at
the expense of private health insurance companies, phys-
ician samples and drugs dispensed during periods of
hospitalization is not available.
The database is not publicly accessible, however studies
utilizing data from the DAPI database can be performed
on request - subject to the condition that the purpose of
the study complies with the DAPI’s statutes. The DAPI is a
non-profit association aiming at the advancement of scien-
tific research in drug utilization and drug safety.
Ethical approval was not required for the present study,
as (i) the data are routinely collected during the process of
care without an intervention and (ii) the data comprise de-
identified drug claims data being devoid of any personal in-
formation, thus precluding re-identification of patients. The
database and anonymisation procedures were approved by
the responsible data protection authority, at the time of
study the regional administrative authority of Darmstadt in
Hesse, in compliance with German legislation on data priv-
acy and utilization of data from drug claims.
Study design
A cohort study was performed comparing three treat-
ment groups according to the dosage strength of the first
Gb prescription (index prescription) between January 1st
and December 31st 2008:
 patients with an index prescription of 240 mg Gb
dosage strength
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dosage strength
 patients with an index prescription with a dosage
strength of less than 120 mg.
Furthermore, patients had to fulfill the following inclu-
sion criteria:
 incident Gb therapy (i.e. no prescription of Gb
during 365 days before the index date),
 registration in the database 730 to 365 days prior to
index date,
 unambiguous assignment to a study group at the
index date.
Medical information on the exact indication or co-
morbidities as well as demographic information is not
available in the database. However, reimbursement restric-
tions within the SHI scheme allow reimbursement of Gb
only for dementia. Therefore, it can be assumed that Gb
was prescribed for this indication and not for other labeled
indications (such as tinnitus etc.). In addition, the following
covariates have been retrieved from the database for fur-
ther characterization of patients and co-morbidities, and
these were also considered as potential risk factors associ-
ated with non-persistence:
 medical specialty of initial prescriber: general
practitioners, neurologists, internal medicine specialists
and other specialties were considered, as prescribing
behavior may depend on medical specialty,
 region of the prescriber: western and eastern
Germany, as there might be differences in
prescribing Gb, because there is a forty years’
tradition to prescribe Gb in the former Federal
Republic of Germany (west), but not in the former
German Democratic Republic (east),
 insurance membership status at index date:
mandatory member, family member or retired
person, as this variable is a proxy for the
demographic variable age in the database,
 pre-treatment within the 180 days before the index
date with
 further antidementia substances (Anatomical
Therapeutic Chemical (ATC)-code N06D
excluding Gb),
 antidepressants (ATC-code N06A),
 nootropics (ATC-code N06BX),
 or drugs indicating the possibility of a co-existing
disease for which Gb may be used but not
reimbursed: for indication tinnitus: pentoxifylline
(ATC-code C04AD03), for indication peripheral
arterial occlusive disease cilostazol (ATC-code
B01AC23) and naftidrofuryl (ATC-codeC04AX21), and antivertigo preparations
containing betahistine, flunarizine or cinnarizine
(ATC-code N07CA).
 Number of different ATC 3rd level codes per patient
prescribed within the 180 days prior to index date
except those ATC 3rd level codes mentioned above,
as the number of different ATC 3rd level codes
is supposed to indicate indirectly the degree of
co-morbidity.
Patients were excluded if the medical specialty of the
prescribed physician, the region or insurance member-
ship status of the index prescription were not available
or defined ambiguously.
Outcome
Persistence was determined as the primary study out-
come during 365 days following treatment initiation. It
was defined as continuous treatment assuming that any
Gb medication prescribed is completely taken at the rec-
ommended dose of 240 mg per day, with temporal lapses
between subsequent prescriptions not exceeding an allow-
able gap of 20% of the duration of the previous medication
supply [20]. Stockpiling, i.e. medication oversupply due to
early refill of a prescription, was taken into account in
the calculation of persistence. Any switch to another Gb
medication (different drug product and/or different dosage
strength) after the index prescription was permitted and
was not regarded as treatment discontinuation. If a patient
had not refilled a prescription within a predetermined
number of days after running out of medication supply
plus the allowable gap of 20%, the patient was considered
to have discontinued therapy and therefore was classified
as non-persistent at the end of the allowable gap [21]. Pa-
tients were censored if they were lost to follow-up (i.e.
recording of the last prescription of any drug in the data-
base) or at the end of the study period (12 months after
the index date). A change of the prescribing physician did
not result in loss to follow-up.
The persistence definition requires assumptions about
the prescribed daily dose (i.e. 240 mg). However, the pre-
scribed daily dose is not available in the reimbursement
database and may not apply to all patients, e.g. if pre-
scribers deliberately chose a lower dose for an individual
patient. Therefore, two additional measures of treatment
continuation were employed, which do not depend on a
dosage assumption. First of all, the length of therapy was
used to calculate the proportion of days covered with
Gb medication from the index date to the date of the
last Gb prescription within the study period (12 months)
assuming that the patient had been dispensed enough
medication to cover the interjacent period. Patients with-
out a refill prescription were by definition excluded from
this analysis. Secondly, the number of patients with at least
Czeche et al. BMC Complementary and Alternative Medicine 2013, 13:278 Page 4 of 10
http://www.biomedcentral.com/1472-6882/13/278one subsequent refill prescription within 12 months after
the index prescription was determined.
Furthermore, we investigated the proportion of pa-
tients changing their study group, i.e. who switched be-
tween Gb products of different dosage strengths.
Statistical analyses
For persistence, length of therapy and refill prescrip-
tions, descriptive statistics (i.e. proportions and me-
dian values) were determined. A log-rank test was used
to compare persistence between the three study co-
horts and Cox proportional hazard models were con-
ducted to identify and control for factors associated
with non-persistence. For the analyses of the propor-
tion of patients with a refill prescription, logistic re-
gression models were used. Significance levels were set
at α = 0.05.
All statistical analyses were performed using SPSS for
Windows version 14 and R version 2.13.0.
Results
Cohort attrition
In the DAPI database, 50,995 patients were identified
who received at least one prescription of Gb during the
index period between January 1st and December 31st
2008. Pre-treatment with Gb during 365 days prior to
index date was the main reason for exclusion of the ma-
jority of patients (i.e. 41.6%) from the cohort. Nearly a
quarter of patients (25.3%) lacked availability in the data-
base in the period of 730 – 365 days before index date.
After implementation of all inclusion and exclusion cri-
teria, 13,810 patients remained in the final study cohort,
of whom 430 patients (3.1%) were treated with Gb at a
strength of 240 mg, 7,070 patients (51.2%) at a strength
of 120 mg and 6,310 patients (45.7%) at strengths of less
than 120 mg (i.e. 30, 40, 50, 60 or 80 mg) at the date of
the index prescription (see Figure 1).
Characterization of the final study population
The baseline characteristics of the study groups are de-
tailed in Table 1. As Gb with a strength of 240 mg in
one tablet had just been introduced on the German mar-
ket in 2008 [22], the lowest proportion of patients (430
patients or 3.1% of total study cohort) received prescrip-
tions with this strength, while a similar number of pa-
tients were prescribed strengths of 120 mg or less than
120 mg (7,070 and 6,310 patients or 51.2% and 45.7% of
total study cohort, respectively). Generally, Gb medica-
tion has mainly been prescribed by general practitioners.
However, the proportion of patients receiving prescrip-
tions of 240 mg or 120 mg Gb strength was higher in
the group of neurologists (32.3% and 28.8% respectively),
while physicians of other specialties tended to more
frequently issue prescriptions for less than 120 mg Gbstrength. The majority of all patients receiving Gb were
retired (74.3% – 82.1%). Within the pre-treatment period
of 180 days before the index date, only few patients re-
ceived co-medication with drugs for indications possibly
related to Gb use (i.e. antidementia agents, nootropics,
drugs used for the treatment of peripheral arterial occlu-
sive disease, vertigo or tinnitus). For example, antide-
mentia agents were used in 8.0% to 12.6% of patients.
However, pre-treatment with antidepressants was quite
common (38.0% – 44.4%). Polypharmacy, defined as pre-
scriptions of 5 or more different ATC 3rd level drugs
within 180 days before the index date, was present in
approximately 80% of the patients.
Results of the follow-up period of 365 days
In the study group treated with 240 mg Gb at the index
date, the proportion of persistent patients was higher
compared to the other study groups. Kaplan-Meier curves
of treatment persistence with Gb medication until discon-
tinuation of therapy are shown in Figure 2. Differences
between the study groups were statistically significant
(log-rank test, p < 0.0001). The staircase pattern of the
curves results from the different package sizes that were
dispensed. Median duration of persistence was 97, 73 or
21 days for patients treated initially with 240 mg, 120 mg,
or less than 120 mg Gb dosage strength, respectively. After
6 months, cumulative probability of persistence was 22.8%
for patients treated with 240 mg Gb dosage strength, 5.7%
for 120 mg dosage strength and already close to 0% for pa-
tients treated with less than 120 mg Gb dosage strength.
After 12 months, only 8.4% of patients with 240 mg Gb
and 2.1% with 120 mg Gb were still persistent.
In the unadjusted Cox regression model the risk for
being non-persistent was decreased by 37% for patients
treated with 240 mg Gb dosage strength vs. 120 mg (HR
0.63; 95% CI: 0.57 – 0.70), whereas the risk for non-
persistence was increased by 4.5 times for patients treated
with less than 120 mg dosage strength vs. 120 mg (HR
4.54; 95% CI: 4.36 – 4.73). In the adjusted multivariate
Cox regression model, further covariates were associated
with a reduced risk for non-persistence, e.g. neurologist as
medical specialty of prescribing physician at index date,
eastern Germany as region of the prescriber or pre-
treatment with antidementia drugs (see Table 2). Con-
versely, the hazard for non-persistence was increased for
patients with insurance status member or family member
(relative to retired persons).
As the persistence method depends on the assumption
of a prescribed daily dose of 240 mg, further dose-
independent measures of treatment continuation were
employed. The length of therapy was calculated as the time
between the first and last Gb prescription during the obser-
vation period of 12 months after the index date, assuming
that the patient had been dispensed enough medication to
Figure 1 Inclusion and exclusion criteria of the study cohort.
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lysis, only patients with at least one refill prescription were
included (5,583 patients out of 13,810 in the total study co-
hort). The median of the length of therapy was highest
with 281 days in the 240 mg Gb group followed by 250 days
in the 120 mg group and 225 days in the group of patients
treated with Gb dosage strengths of less than 120 mg, con-
firming the results from the persistence analysis. After
6 months, 68.2% of the 240 mg Gb patients, 63.4% of the
120 mg Gb patients and 57.9% of the patients treated with
less than 120 mg dosage strengths were considered to be
supplied with Gb medication.
As a further dose-independent method we determined
the proportion of patients receiving at least one refill
prescription after the index date. Again, the proportion
of patients refilling at least one prescription was highest
(52.8%) in the group of patients initially treated with
240 mg strength compared to 45.3% of patients treatedwith 120 mg and 34.1% of patients treated with less than
120 mg dosage strength. For logistic regression analysis,
only patients with continuous follow-up in the DAPI data-
base for at least 12 months after index date were included
(12,191 patients out of 13,810 in the total study cohort).
The unadjusted odds for receiving a refill prescription was
increased for Gb 240 mg patients by 29% (OR 1.29; 95%
CI: 1.05 – 1.59) and decreased for less than 120 mg Gb pa-
tients by 37% (OR 0.63; 95% CI: 0.58 – 0.68) relative to the
group of patients treated with 120 mg Gb dosage strength.
A similar association was found in the adjusted model: The
odds to obtain a refill prescription was increased by 28%
for 240 mg Gb patients (OR 1.28; 95% CI: 1.03 – 1.58)
whereas it was decreased by 23% for less than 120 mg Gb
(OR 0.77; 95% CI: 0.71 – 0.83) relative to patients treated
with 120 mg Gb dosage strength.
Similar to the associations observed in the Cox re-
gression analysis of persistence, the covariates internal
Table 1 Baseline characteristics of the study cohorts
Number of patients (% of study group)
240 mg dosage strength 120 mg dosage strength < 120 mg dosage strength
Number of patients 430 7,070 6,310
Medical specialty of initial prescriber
General practitioner 182 (42.3) 3,230 (45.7) 2,978 (47.2)
Neurologist 139 (32.3) 2,038 (28.8) 887 (14.1)
Internist 56 (13.0) 950 (13.4) 896 (14.2)
Other 53 (12.3) 852 (12.1) 1,549 (24.5)
Region of the initial prescriber
Western Germany 299 (69.5) 5,499 (77.8) 5,500 (87.2)
Eastern Germany 131 (30.5) 1,571 (22.2) 810 (12.8)
Insurance membership status
Retired 353 (82.1) 5,814 (82.2) 4,687 (74.3)
Mandatory member 62 (14.4) 1,029 (14.6) 994 (15.8)
Family member 15 (3.5) 227 (3.2) 629 (10.0)
Pre-treatment 180 days prior to index date with
Antidepressants 181 (42.1) 3,136 (44.4) 2,395 (38.0)
Antidementia drugs 54 (12.6) 782 (11.1) 505 (8.0)
Nootropics 24 (5.6) 379 (5.4) 236 (3.7)
Antivertigo preparations (betahistine/flunarizine/cinnarizine) 50 (11.6) 720 (10.2) 639 (10.1)
Pentoxifylline 16 (3.7) 372 (5.3) 366 (5.8)
Drugs for treatment of peripheral arterial occlusive disease
(cilostazol/naftidrofuryl)
16 (3.7) 189 (2.7) 181 (2.9)
≥ 5 different ATC third level drugs within 180 days prior to
index date
357 (83.0) 5,850 (82.7) 5,023 (79.6)
Patients with follow-up prescription 227 (52.8) 3,202 (45.3) 2,154 (34.1)
Figure 2 Kaplan-Meier curves showing the cumulative
probabilities of continuation of therapy (persistence) in patients
treated at index prescription with Gb at 240 mg dosage strength,
120 mg dosage strength, or less than 120 mg dosage strength.
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as region of the prescribing physician as well as pre-
treatment with antidementia drugs were associated with
increased odds for a follow-up prescription, while insur-
ance status member and family member were associated
with reduced odds for a follow-up prescription relative to
retired persons. Further covariates with a positive associ-
ation of receiving a refill prescription were pre-treatment
with antidepressants (OR 1.11; 95% CI: 1.03 – 1.26) and
nootropics (OR 1.46; 95% CI: 1.23 – 1.73) in the logistic re-
gression model.
However, the results from both regression models are
limited by a lack of goodness-of-fit (i.e. the c-statistic for
the logistic regression model was only 0.647) and in case
of the Cox regression models by violations of the pro-
portional hazard assumption.
Finally, switching the dosage strength during follow-up
occurred only rarely: in the 240 mg Gb and less than
120 mg Gb groups, the proportions of patients switching
the dosage strength were similar (13.2% and 12.9%, re-
spectively), whereas in the 120 mg Gb group merely
7.3% of patients switched the dosage strength.
Table 2 Adjusted hazard ratios (HR) for non-persistence and 95% confidence intervals (CI) in the Cox regression model
Adjusted HR 95% CI
Study group (ref. 120 mg Gb dosage strength)
240 mg Gb dosage strength 0.64 * 0.57-0.71
< 120 mg Gb dosage strength 4.36 * 4.18-4.54
Medical specialty of initial prescriber (ref.: general practitioner)
Neurologist 0.93 * 0.89-0.97
Internist 0.96 0.91-1.01
Other 1.43 * 1.36-1.50
Region of initial prescriber (ref.: Western Germany)
Eastern Germany 0.74 * 0.71-0.77
Insurance membership status (ref.: retired)
Mandatory member 1.23 * 1.17-1.29
Family member 1.61 * 1.50-1.73
Pre-treatment 180 days prior to index date (ref.: none)
Antidepressants 0.97 0.93-1.01
Antidementia drugs 0.86 * 0.81-0.91
Nootropics 0.92 0.85-1.00
Antivertigo preparations (betahistine/flunarizine/cinnarizine) 0.99 0.94-1.05
Pentoxifylline 1.07 0.99-1.15
Drugs for treatment of peripheral arterial occlusive disease (cilostazol/naftidrofuryl) 0.99 0.89-1.10
Number of different ATC third level drugs prescribed within 180 days prior to index date 1.00 1.00-1.00
* HR significant at p < 0.05.
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In the present study, a large cohort of 13,810 patients
was identified from the DAPI database with a first pre-
scription for Gb medication in 2008. Continuation of
drug therapy within 12 months from treatment initiation
was generally lower than expected in this cohort, although
it was significantly higher in patients initiating therapy with
the 240 mg dosage strength. After 6 months, the cumula-
tive probability of persistence of patients in the 240 mg,
120 mg, or less than 120 mg groups decreased to 57.4%,
22.8%, or nearly 0%, respectively, and after 12 months to
8.3% in the 240 mg Gb group and to 2.1% in the 120 mg
Gb group. Likewise, only a low proportion of patients filled
a second prescription after Gb treatment initiation: 52.8%
in the 240 mg dosage strength group, 45.3% in the 120 mg
group and 34.1% in the less than 120 mg group. In analogy
to the measures of persistence and refill prescriptions, the
length of therapy was highest for patients treated with
240 mg dosage strength compared to study groups with
lower dosage strengths.
These results imply that Gb drugs containing the rec-
ommended daily dose of 240 mg in a single tablet might
be favorable for patients’ persistence - although accord-
ing to the current label the tablet should be split and
one half taken twice a day [22], i.e. the dosage interval
thus remains unaltered compared to twice daily dosingof Gb products with 120 mg dosage strength. Neverthe-
less, we cannot exclude that patients may use the 240 mg
product once daily, as this may be more practicable in
real-life settings for patients with cognitive impairment
and their care-givers [23]. A simpler and less frequent
doses regime may increase patients’ adherence [16,17]. The
efficacy and safety of a once daily regimen of 240 mg EGb
761W has been demonstrated in several major placebo-
controlled trials [13,14]. Hence, presumed once-daily
dosing of the 240 mg Gb products - albeit contrary to the
dosage instructions from the package insert - may in part
explain the higher adherence (persistence) observed in the
present study.
Noting that treatment duration of dementia should be
at least 12 weeks [7,24] the persistence after 3 months
may be sufficient only for the 240 mg Gb cohort of pa-
tients, whereas it is most probably inadequate for the
other study groups. However, we cannot exclude that
persistence in real-life is better than calculated from SHI
reimbursement data, where data on self-medication are
unavailable – especially since Gb is available without pre-
scription and the largest share of Gb drugs in Germany is
purchased via self-medication [25].
The low persistence levels observed in our study may
also be explained by discontinuation of the drug due to
side effects. However, serious side effects of Gb that
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served in previous studies. Results of a meta-analysis
have shown that the rates of side effects and discontinu-
ation were not different between EGb 761W and placebo
[26]. The dropout rates in clinical trials of Gb have been
variable, ranging from 1% to 62% [26], which may indi-
cate that other factors, e.g. age, co-morbidities, personal-
ity traits [27] or unrealistic expectations on treatment
effects may be associated with or explain discontinuation
of Gb treatment.
Direct comparisons of persistence results from this
study with other investigations are difficult, because, to the
best of our knowledge, other data from large population-
based non-interventional cohort studies with Gb treatment
are not available. Nevertheless, persistence of patients with
dementia was evaluated for ChEI or memantine, albeit
with differences in the definition of persistence, inclusion
and exclusion criteria or other operational definitions. A
recent study based on SHI data in Germany reported that
patients with dementia only rarely received continuous
prescriptions with an appropriate dosage in each of four
quarter years after treatment initiation: 44% of patients
treated with ChEIs and 15% of patients treated with mem-
antine [9]. Studies from other countries reported on
persistence rates at 12 months of 33.6% for the ChEI
donepezil and rivastigmine in Canada [28] and 45.3% for
the ChEI rivastigmine and galantamine in France [29].
Persistence results from these studies with an allowable
gap of 60 days between refills are higher compared to the
Gb persistence rates in the present study where a gap of
only 20% was allowed. As the 20% allowable gap is in all
cases considerably lower than 60 days (e. g. for a prescrip-
tion of 120 tablets with the longest coverage, the 20% al-
lowable gap are 44 days after depletion of the package),
these differences in methodology readily explain the lower
persistence observed in our study. In the present study a
relatively small gap was chosen, because Gb should be
taken continuously with at the utmost only small gaps for
its efficacy. Furthermore, instead of an absolute number of
days as allowable gap, a relative gap of 20% was chosen in
order to allow for the variable package sizes available on
the market.
In the pre-treatment period, a large proportion of pa-
tients of all 3 study groups frequently received antide-
pressants. Findings from various studies have shown that
there is evidence for an association between late-life de-
pression and dementia, especially Alzheimer’s disease
(AD) [30-32]. Still it is not clear whether a depression
history is a risk factor for AD or whether neuropatho-
logic changes in AD may result in a depression. However,
the close relationship between both diseases could be a
possible explanation that nearly half of patients across all
three Gb treatment groups received antidepressants in
the present study. Therapy with antidepressants was notassociated with persistence and showed only a weak, but
positive association with the odds of filling a refill pre-
scription. In conclusion, the use of antidepressants in the
present study does not seem to have a negative effect on
persistence with Gb therapy.
The proportion of patients with pre-treatment with any
antidementia drug was approximately equal, but low, in all
study groups. Thus, it appears that patients in the present
cohort suffer from mild to moderate symptoms of demen-
tia, where Gb may be chosen as first treatment option be-
fore medication with ChEI or memantine was initiated.
Alternatively, other antidementia drugs may not have been
considered suitable for patients due to contraindications,
interactions, side effects, or other than labeled dementia
diagnoses. Although ChEI are among the recommended
first-line drugs in the treatment of mild to moderate stages
of AD [33], their use is limited due to side effects such as
gastrointestinal disorders, dizziness, anorexia, or tremor
[34]. For the group of patients pretreated with antidemen-
tia drugs, augmentation of therapy with Gb might have
been pursued by the prescriber. There is evidence that a
combination of both, ChEI and Gb, may be superior to a
monotherapy with only ChEI or Gb and will be associated
with efficacy and less side effects, as shown in an explora-
tory trial with donepezil and EGb 761W [35].
The present study has several limitations which should
be taken into account for interpretation of results. Firstly,
because in the database no information about drugs dis-
pensed by community pharmacies without prescription
(self-medication) or prescriptions at the expense of private
health insurance companies is available, patients may be
incorrectly interpreted as non-persistent, as already stated
above. This also implies that the observed differences in
persistence between different dosage strengths of Gb in
this study may be biased if Gb medication acquisition via
self-medication is non-differential for the different dosage
strengths – although there is neither data available to sup-
port or refute this hypothesis. Moreover, patients may have
incorrectly been classified as non-persistent due to periods
of hospitalization or provision of free medication samples
from their physician. Therefore, the persistence of patients
taking Gb would be higher if all routes of medication sup-
plies could have been captured. On the other hand, persist-
ence may be overestimated from claims data, since it is
assumed that any medication dispensed is completely
taken by the patient, which is probably not the case.
Secondly, as in any observational and non-randomized
study, the differences in persistence between the study
groups treated with different Gb dosage strengths may
be biased by unmeasured, and hence uncontrolled con-
founding. For example, a previous study found associa-
tions between age, personality factors, cognitive function
and Gb adherence [27]. Such variables were not available
in the present study. However, insurance membership
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and age was included in the regressions models and an
association with improved persistence for retired per-
sons relative to other insurance membership categories
was found, which confirms previous findings that socio-
economic factors or age may indeed affect Gb persist-
ence. Nevertheless, we cannot exclude that confounder
control with this proxy variable is still limited.
Furthermore, choice of Gb dosage strength may be re-
lated to physician factors such as prescribing preference,
which in turn may be either directly or indirectly associ-
ated with different persistence with drug therapy. Little
is known about physician prescribing preferences for de-
mentia drugs [9] or more specifically for Gb [8]. Although
a recent study reported on neurologists preferentially pre-
scribing other antidementia drugs relative to Gb [8], data
on prescribing preferences with regard to choosing the
dosage strength of Gb are unavailable to the best of our
knowledge. Also, direct evidence of an association between
physician-related factors and persistence with dementia
treatment is lacking, although an observational study re-
ported that medication review by doctors was associated
with better medication adherence in elderly patients [36].
The results from the present study suggest (i) that neu-
rologists preferentially prescribe Gb with higher dosage
strengths as well as (ii) that being treated by a neurologist
is associated with better persistence, hence a potential con-
founding effect of physician-related factors on persistence
cannot be ruled out. In summary, although available covar-
iates such as specialty of prescribing physician were in-
cluded in multivariate models in the present study, further
important confounders may have been missed and associa-
tions between different Gb dosage strengths and persist-
ence may still be biased by unmeasured confounding [37].
Thirdly, the persistence calculation required assump-
tion of a prescribed daily dose and may not reflect the real
daily dose for all patients. However, the dose-independent
measures of therapy continuation led to essentially the
same conclusions.
A strength of the current study is the size of the DAPI
database covering more than 80% of community pharma-
cies throughout Germany. Hence, the sample of patients in
the current study can be assumed to be representative for
the SHI scheme. Moreover, refill persistence – as opposed
to patient-reported measures – can be regarded as an ob-
jective measure of medication adherence [15].
Conclusions
The results from this study provide evidence that treat-
ment duration with Gb therapy is insufficient in a signifi-
cant proportion of patients to receive the achievable
benefit of therapy. Physicians and pharmacists alike should
make efforts to stress the importance of adequate Gb per-
sistence to patients, caregivers and relatives. Moreover, adosage strength of 240 mg contained in a single dosage
form – i.e. the recommended dosage for treatment of de-
mentia per day – appears to be advantageous, especially
for older patients with cognitive impairments who are
often in need to take numerous other drugs. This observa-
tion deserves confirmation in prospective studies.
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